Marion Subklewe, Amir Fathi, and Andrew Wei discuss emerging immunotherapies, venetoclax-based regimens, and targeted therapies in AML. They explore challenges in translating successful treatment strategies, discuss treatment options and challenges for TP53 mutated AML patients, and highlight the importance of targeted therapies. The speakers also delve into designing frontline phase three studies for older AML patients and the challenges of label expansion for emerging immunotherapies.
